Connect with us

Health

COVID-19: NAFDAC grants coys conditional use of antibodies, antigen test kits

Published

on

The National Agency for Food and Drug Administration and Control (NAFDAC) has granted conditional approval for use of antibodies, antigen test kits and Personnel Protective Equipment (PPEs) for companies and importers manufacturing them for Coronavirus (COVID-19) patients.

Director General of NAFDAC, Prof. Mojisola Adeyeye, said in a statement issued in Abuja that the approval was done in pursuant of the powers conferred on the Agency to take such decision.

According to her,

 

the power conferred on the agency is contained in Section 5 of the NAFDAC Act which empowered it to regulate and control the manufacture, importation, exportation distribution sale, use and advertisement of medical devices.

The director general said the current COVID-19 pandemic had necessitated that NAFDAC put measures in place to ensure access to health commodities that had the potential to impact positively on public health outcomes.

“These include, but are not limited to, diagnostics necessary to support public health infrastructure and guide the response necessary to combat and address the pandemic.

“The antibody test kits (IggM) can be used in COVID-19 confirmed individuals, who can then be tested at the designated centers using the antibody kits to confirm that they have antibodies and as such may not be infected again.

“The antigen tests kits on the other hand, can detect the COVID-19 antigen in patients with or without symptoms. The results are only qualitative (positive or negative).

“There has been a global effort by innovative diagnostic companies to develop test kits to aid in detection of the virus in patients to guide the management of the disease,’’ she said.

According to her, the Agency recently received many requests for Emergency Use Authorisation for some of such diagnostic test kits to support the national response and ensure expanded testing capabilities.

She said NAFDAC had put in place regulatory measures to ensure quality, safety and efficacy criteria are assessed, and that these measures were supported by documentation.

She said these included prior registration and approval by reference regulatory authorities such as those of Japan, USA, Germany, Canada, European Medicine Agency, etc. Registration by the Regulatory Authority in the Country of Manufacture.

Others are, Declaration of Conformity and Validation/performance evaluation /Clinical Evaluation Report.

In addition, Adeyeye said NAFDAC was part of the African Medical Devices Forum (AMDF), a Technical Working Group of African Medical Products Regulatory Harmonization (AMRH) that had a joint secretariat with World Health Organisation (WHO).

“Deliberations of the Forum that will be shared with the AMRH Steering Committee for approval and implementation, will further guide NAFDAC.

“Some of the technical issues that will come out of the deliberations include updates on the list of COVID-19 in vitro diagnostics and medical devices, substandard and falsified commodities and handling of donations.

“NAFDAC will continue to stay abreast of current best

 

global practices in this area and monitor updates to the WHO collated list of medical devices being used by different countries.

“In addition to these requirements, the full approval of any diagnostic/test kit by NAFDAC for COVID-19 will be subject to in-country validation to assess the sensitivity or rate of failure (i.e., indication of false positives), and specificity.

“Failure to comply could lead to revocation of any approval granted for importation of the products and forfeiture of same to the agency for destruction,’’ she said.

The director-general also said NAFDAC had reduced the “registration to approval” time from 120 working days to 10 working days due to the COVID-19 pandemic.

Thus far, she said the Agency had processed 17 applications using the expedited review process but has only granted Emergency approval to seven companies using the criteria listed above.

“The availability of Personal Protective Equipment (PPE) for health care providers is a critical component of the effort to stem the COVID 19 pandemic.

“These PPEs include gloves, protective goggles, face shields, protective

 

gowns and masks in the form of particulate respirators and surgical masks.

“These must meet certain technical requirements and specifications in order to achieve the objective and offer some measure of protection to health care providers and limit their exposure to infection .

“Please note, no vaccines have been approved for any clinical trial. That may not happen before one year to eighteen months, after clinical trials must have been conducted in different countries.

“This will be followed by rigorous in-country assessment in line with laid down protocols to further ensure safety and efficacy,’’ she added.

Edited By: Salif Atojoko
(NAN)